61564-89-4

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-PROPOXYBENZALDEHYDE is used as an intermediate in the synthesis of pharmaceuticals for its versatile building block properties in organic chemistry.
Used in Organic Chemistry:
5-BROMO-2-PROPOXYBENZALDEHYDE is used as a reagent for the preparation of various functionalized benzaldehydes, contributing to the development of new organic compounds.
Used in Drug Development:
5-BROMO-2-PROPOXYBENZALDEHYDE is used in the development of new drugs and pharmaceutical products due to its structural properties and reactivity.
Used in Chemical Research:
5-BROMO-2-PROPOXYBENZALDEHYDE is used in chemical research to explore its potential applications and reactions in various chemical processes.
Used in Industrial Applications:
5-BROMO-2-PROPOXYBENZALDEHYDE may be used in industrial applications for its versatility and reactivity in the synthesis of various organic compounds.

InChI:InChI=1/C10H11BrO2/c1-2-5-13-10-4-3-9(11)6-8(10)7-12/h3-4,6-7H,2,5H2,1H3

Upstream product

• 106-94-5 propyl bromide 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 279262-21-4 5-bromo-2-n-propoxybenzonitrile 
• 191034-25-0 L 168049 

Relevant academic research and scientific papers

COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND COMPOSITIONS AND USES THEREOF

Scaffold compounds are used to design small molecule compounds and structure- activity relationship studies identify inhibitors of inflammation· Methods include pharmaceutical compositions of the small molecule compounds to inhibit, prevent and treat dise

Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability

We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-place preference assays in mice, and do not produce dependence. Although these attributes are promising, these analogues exhibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinoline scaffold in this series. As such, a structure-activity relationship (SAR) campaign was pursued to improve their metabolic stability. This resulted in a shift from our original bicyclic tetrahydroquinoline core to a monocyclic benzylic-core system. By eliminating one of the rings in this scaffold and exploring the SAR of this new core, two promising analogues were discovered. These analogues (5l and 5m) had potency and efficacy values at MOR better or comparable to morphine, retained their DOR-antagonist properties, and showed a 10-fold improvement in metabolic stability.

Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

NLRP3 inflammasomes have recently emerged as an attractive drug target for neurodegenerative disorders. In our continuing studies, a new chemical scaffold was designed as selective inhibitors of NLRP3 inflammasomes. Initial characterization of the lead HL

Anilide derivative, production and use thereof

This invention is to provide a compound of the formula: wherein R1is an optionally substituted 5- to 6-membered ring; the ring A is an optionally substituted 6- to 7-membered ring; the ring B is an optionally substituted benzene ring; n is an integer of 1 or 2; Z is a chemical bond or a divalent group; R2is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of the formula: ?wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R5and R6are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R5and R6may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof , which is useful for antagonizing CCR5 and also for the prevention and treatment of infectious disease of HIV.